MediWound Ltd. (MDWD) - Form 20-F Summary
Business Context and Reporting Period
Company: MediWound Ltd.
Reporting Period: Fiscal year ended December 31, 2015
Jurisdiction: Israel (Foreign Private Issuer)
Accounting Standard: International Financial Reporting Standards (IFRS)
Business Overview: MediWound is a biopharmaceutical company focused on developing and commercializing products based on patented proteolytic enzyme technology. Its lead product, NexoBrid, is approved in the European Union, Israel, and Argentina for the non-surgical removal of eschar in severe burns. The company is currently commercializing NexoBrid in Europe and Israel while advancing a U.S. Phase 3 pivotal study to support FDA approval. The company also has pipeline candidates for chronic wounds (EscharEx) and connective tissue disorders.
Key Financial Metrics (Year Ended Dec 31, 2015)
| Metric | 2015 (in thousands) | 2014 (in thousands) |
|---|---|---|
| Revenues | $601 | $259 |
| Cost of Revenues | $2,519 | $2,785 |
| Gross Loss | $(1,918) | $(2,526) |
| Operating Expenses (Total) | $19,309 | $18,901 |
| - R&D (Net of participations) | $6,021 | $5,349 |
| - Selling & Marketing | $9,284 | $8,829 |
| - General & Administrative | $4,004 | $4,723 |
| Operating Loss | $(21,227) | $(21,427) |
| Net Loss | $(22,088) | $(18,875) |
| Net Loss Per Share (Basic/Diluted) | $(1.02) | $(0.95) |
| Cash and Cash Equivalents | $45,768 | $64,853 |
| Working Capital (Net) | $45,189 | $64,600 |
| Total Shareholders' Equity | $23,470 | $42,871 |
Note: The company reported a loss from discontinued operations of $417,000 in 2015 related to the PolyHeal product license termination.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 132% to $0.6 million, driven by expanded sales of NexoBrid in Europe and Israel following the 2014 launch.
- Cost of Revenues: Decreased 10% to $2.5 million, primarily due to a reduction in share-based compensation expenses and an increase in finished goods inventory.
- R&D Expenses: Gross R&D expenses increased 34% to $8.1 million due to higher employee costs, initiation of clinical trials, and manufacturing costs for NexoBrid and EscharEx. Net R&D expenses (after government grants) increased to $6.0 million.
- Selling & Marketing: Increased 5% to $9.3 million, reflecting a full year of headcount for the European sales force.
- General & Administrative: Decreased 15% to $4.0 million, largely due to a $0.9 million reduction in equity-based compensation, partially offset by higher professional fees associated with being a public company.
- Liquidity: Cash and cash equivalents decreased by approximately $19 million to $45.8 million, primarily due to operating losses and investing activities, despite receiving government grants and BARDA funding.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance:
- The company expects to continue incurring significant operating losses for the foreseeable future as it invests in R&D, clinical trials, and commercial expansion.
- Plans to launch NexoBrid in Argentina in the first half of 2016.
- Top-line results for the U.S. Phase 3 pivotal study are expected in the first half of 2017.
- Top-line results for the EscharEx Phase 2 study are expected in February 2016.
Key Risks:
- Commercialization: Success depends heavily on the commercial performance of NexoBrid in Europe and obtaining FDA approval in the U.S.
- Regulatory: Failure to obtain U.S. FDA approval or delays in the Phase 3 study would materially impact prospects. The company is subject to post-marketing commitments in Europe.
- Supply Chain: Reliance on a single supplier (Challenge Bioproducts Corporation Ltd.) for the intermediate drug substance (bromelain SP).
- Manufacturing: All manufacturing is concentrated in a single facility in Yavne, Israel, exposing the company to risks of force majeure events (e.g., war, natural disaster).
- Legal Proceedings: Ongoing litigation with PolyHeal shareholders regarding a potential $1.5 million obligation to purchase shares, contingent on funding from Teva (which has not been received).
Unusual Items:
- BARDA Contract: In September 2015, the company was awarded a contract by the U.S. Biomedical Advanced Research and Development Authority (BARDA) valued at up to $112 million. As of year-end, $0.8 million was recorded in funding.
- Government Grants: Significant R&D expenses are offset by grants from the Israeli Office of the Chief Scientist (OCS) and BARDA.
Investor Verification Checklist
- U.S. Regulatory Path: Verify the enrollment status and interim data of the U.S. Phase 3 pivotal study for NexoBrid, as FDA approval is critical for long-term growth.
- Commercial Execution: Monitor quarterly revenue growth rates in Europe to assess market acceptance and reimbursement success.
- Liquidity Runway: Confirm that the $45.8 million cash balance is sufficient to fund operations through the completion of the U.S. Phase 3 study and potential FDA submission, given the continued net losses.
- Legal Contingencies: Track the status of the PolyHeal litigation and the potential $1.5 million liability exposure.
- Supply Chain Security: Assess the stability of the relationship with the sole supplier of bromelain SP and the adequacy of inventory buffers.